duvakitug

News

Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.

News

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.